The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016

Date: May 22, 2011
Pages: 81
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A4B154C55E1EN

Download PDF Leaflet

The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
Global License: US$ 14,780.00


The report provides an in-depth analysis of the respiratory franchise. It also Highlights the key R&D trends that may influence treatment sales and includes a thorough analysis of the competitive dynamics of leading brands within each indication, enabling the reader to identify growth of the leading brands, key drug classes and leading players through 2016.

Features and benefits
  • Quantify patient potential and assess treatment trends and sales patterns across the major respiratory indications in the seven major markets.
  • Discover which indications have the greatest potential to provide growth and understand the growth drivers of the major drug classes.
  • Analyse the respiratory franchises of top pharmaceutical companies across major indications, and evaluate the market share of these companies.
  • Gain comprehensive understanding of how recent events are affecting the performance of major products and companies.
  • Forecast sales of the leading products as well as key pipeline products in the respiratory market over the period 2010–16.

The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment.

Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical companies, with an estimated 300 compounds in various stages of development. The COPD and allergic rhinitis pipelines are of lesser strength, comprising around 140 products.

Among several once-daily LABA/LAMA combinations in development, Boehringer Ingelheim’s BI1744/Spiriva is at an advantage as this combination product uses the current gold standard COPD treatment Spiriva. Other promising Phase III compounds in development include: Novartis’s NVA237 (glycopyrrolate) and GSK’s 642444 (vilanterol trifenatate). Novart

Your key questions answered
  • What will be the major growth indications and the accompanying growth drivers in the global respiratory market over the period to 2016?
  • Which companies have the strongest respiratory portfolios and ?
  • What are the promising compounds in clinical development for major respiratory indications, and what is their forecast commercial potential?
  • What are the current trends within the major therapy areas such as asthma/COPD and allergic rhinitis across the seven major markets?
  • What are the recent regulatory changes in the respiratory arena and what will be thier impact on the marketed products?
Executive Summary
  Overview and epidemiology of respiratory disorders
  Global market analysis
  Pipeline analysis
  Competitive landscape
About the author
Overview and epidemiology of respiratory disorders
    Disease overview
    Diagnosis, treatment and management
    Forecast epidemiology
    Disease overview
    Diagnosis, treatment and management
    Forecast epidemiology
  Allergic rhinitis
    Disease overview
    Diagnosis, treatment and management
    Forecast epidemiology
Global market analysis
  Key events in the global respiratory market
    New FDA recommendations state that LABAs cannot be used as monotherapy
    FDA requires new outcomes studies for currently approved LABAs in asthma
    FDA: inhalers that contain CFCs to be phased out in US
    Merck’s Dulera (formoterol/mometasone) approved by the FDA for asthma
    Forest/Nycomed’s Daxas approved in EU for severe COPD
    SkyePharma’s NDA for Flutiform rejected by FDA
    Novartis’s Xolair rejected by NICE for pediatric asthma
    AstraZeneca launched Symbicort in Japan
    GSK and Mitsubishi Tanabe ended Japanese tie-up for co-promotion of Adoair
  Leading respiratory brands
  Market analysis by drug class
  Drug class analysis
    Asthma/COPD drugs
    Allergic rhinitis drugs
  Respiratory sales forecast to 2016
Pipeline analysis
  Key R&D events
    GSK dropped darotropium from its COPD pipeline
    Spiriva’s safety review reveals that the drug was not associated with CV risk
  Global respiratory pipeline
  Leading drugs in development
  Profiles of key pipeline products
    Recently launched compounds
    New drug application filed
    Phase III compounds
    Phase II compounds
    Pipeline forecasts
Competitive landscape
    Merck & Co.
    Boehringer Ingelheim
    Market size methodology
    Market forecast
    Prevalence of asthma
    Prevalence of COPD
    Prevalence of allergic rhinitis
Skip to top

Allergic Rhinitis - Pipeline Review, H2 2016 US$ 1,600.00 Sep, 2016 · 179 pages

Ask Your Question

The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: